A Setanoians

691 total citations
15 papers, 588 citations indexed

About

A Setanoians is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, A Setanoians has authored 15 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in A Setanoians's work include Cancer Treatment and Pharmacology (6 papers), Cancer therapeutics and mechanisms (5 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). A Setanoians is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Cancer therapeutics and mechanisms (5 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). A Setanoians collaborates with scholars based in United Kingdom, Netherlands and Denmark. A Setanoians's co-authors include Marien Alet Graham, David Kerr, D. Bissett, Peter D. Wilson, J Cassidy, Jane A. Plumb, N Le Bail, Stan B. Kaye, Robert Brown and Helen Mackay and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

A Setanoians

15 papers receiving 574 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A Setanoians United Kingdom	12	316	253	97	62	59	15	588
Darrell Nix United States	9	566 1.8×	329 1.3×	72 0.7×	70 1.1×	78 1.3×	21	876
Ronald Drengler United States	13	296 0.9×	487 1.9×	70 0.7×	104 1.7×	44 0.7×	27	701
Lee R. Tanzer United States	14	473 1.5×	464 1.8×	86 0.9×	62 1.0×	40 0.7×	21	856
Jean-Pierre Bizzari France	14	288 0.9×	267 1.1×	51 0.5×	95 1.5×	37 0.6×	24	515
Beverly A. Teicher United States	15	387 1.2×	240 0.9×	133 1.4×	79 1.3×	19 0.3×	32	665
Teresa Carrascal Spain	9	332 1.1×	190 0.8×	66 0.7×	30 0.5×	35 0.6×	9	587
Kim Edmonds United Kingdom	9	222 0.7×	317 1.3×	75 0.8×	84 1.4×	26 0.4×	16	560
J. H. M. Schellens Netherlands	12	156 0.5×	281 1.1×	59 0.6×	83 1.3×	29 0.5×	18	506
Sikic Bi United States	10	276 0.9×	282 1.1×	24 0.2×	58 0.9×	30 0.5×	13	547
Maura A. Kraynak United States	13	308 1.0×	431 1.7×	108 1.1×	153 2.5×	52 0.9×	19	807

Countries citing papers authored by A Setanoians

Since Specialization

Citations

This map shows the geographic impact of A Setanoians's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Setanoians with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Setanoians more than expected).

Fields of papers citing papers by A Setanoians

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Setanoians. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Setanoians. The network helps show where A Setanoians may publish in the future.

Co-authorship network of co-authors of A Setanoians

This figure shows the co-authorship network connecting the top 25 collaborators of A Setanoians. A scholar is included among the top collaborators of A Setanoians based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Setanoians. A Setanoians is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Appleton, Kim, Helen Mackay, Ian Judson, et al.. (2007). Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors. Journal of Clinical Oncology. 25(29). 4603–4609. 191 indexed citations

McLeod, Howard L., et al.. (1996). Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. European Journal of Cancer. 32(9). 1518–1522. 22 indexed citations

McLeod, HL, J. Wanders, A Setanoians, et al.. (1996). Multicentre phase II pharmacological evaluation of rhizoxin. British Journal of Cancer. 74(12). 1944–1948. 32 indexed citations

Plumb, Jane A., Gordon Wishart, A Setanoians, et al.. (1994). Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. Biochemical Pharmacology. 47(2). 257–266. 16 indexed citations

Cassidy, James T., Martin A. Graham, W ten Bokkel Huinink, et al.. (1993). Phase I clinical study of LL-D49194?1 with retrospective pharmacokinetic investigations in mice and humans. Cancer Chemotherapy and Pharmacology. 31(5). 395–400. 6 indexed citations

Bissett, D., A Setanoians, J Cassidy, et al.. (1993). Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.. PubMed. 53(3). 523–7. 123 indexed citations

Graham, Marien Alet, D. Bissett, A Setanoians, et al.. (1992). Prelinical and Phase I Studies With Rhizoxin to Apply a Pharmacokinetically Guided Dose-Escalation Scheme. JNCI Journal of the National Cancer Institute. 84(7). 494–500. 21 indexed citations

Kerr, DJ, et al.. (1992). A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. British Journal of Cancer. 65(1). 133–135. 16 indexed citations

Bissett, D., Martin A. Graham, A Setanoians, et al.. (1992). Phase I and pharmacokinetic study of rhizoxin.. PubMed. 52(10). 2894–8. 25 indexed citations

10.

Kerr, David, et al.. (1989). Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients?. Cancer Chemotherapy and Pharmacology. 23(6). 397–400. 14 indexed citations

11.

Gouyette, Alain, et al.. (1988). Flavone acetic acid: a nonlinear pharmacokinetic model. Cancer Chemotherapy and Pharmacology. 22(2). 114–9. 12 indexed citations

12.

Kerr, D J, James T. Cassidy, Christopher Bradley, et al.. (1987). Phase I and pharmacokinetic study of flavone acetic acid.. PubMed. 47(24 Pt 1). 6776–81. 70 indexed citations

13.

Graham, John D., J Cassidy, Matthew W. Harding, et al.. (1986). Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).. PubMed. 46(6). 3142–6. 33 indexed citations

14.

Cunningham, David, M Soukop, J. F. B. Stuart, et al.. (1986). A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488). European Journal of Cancer and Clinical Oncology. 22(11). 1325–1329. 1 indexed citations

15.

Welsh, John, et al.. (1984). The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic technique. Cancer Chemotherapy and Pharmacology. 12(3). 198–200. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact